Myeloma Cell Articles & Analysis: Older
5 articles found
These therapeutic antibodies aim to specifically target antigens on the surface of cells and bind to them, leading to acidic reactions that result in the destruction of target cells. ...
Fc-mediated antibody effector functions include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and anti-dependent cell-mediated phagocytosis ( ADCP), all three effector functions are triggered by the formation of immune complexes, which subsequently recruit complement proteins and/or effector cells. ...
"We found that CAR-T cells did not bind to glioblastoma cells that lack interferon signaling," Larson explained. Although interferon does not directly kill cancer, it makes tumor cells stickier. “In this way, CAR-T cells can better combine with them and eliminate cancer cells.” In contrast, the ...
The key to CAR-T cell therapy is the genetic modification of a patient's body's T cells, which can be collected through a process called apheresis and then shipped to a laboratory, where the cells are modified to contain T cell receptors that recognize specific markers on the surface of cancer cells. ...
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka ...